This one-day hybrid (virtual and in person) workshop will initiate a discussion on expanding epinephrine accessibility and use, including in community settings, to reduce anaphylaxis-related morbidity and mortality. This public workshop is convened by FDA and the Duke-Margolis Institute for Health Policy.